Trademark: 88072409
Word
NANOGENICS
Status
Registered
Status Code
700
Status Date
Tuesday, July 14, 2020
Serial Number
88072409
Registration Number
6098589
Registration Date
Tuesday, July 14, 2020
Mark Type
4000
Filing Date
Thursday, August 9, 2018
Published for Opposition
Tuesday, February 25, 2020

Trademark Owner History
Nanogenics Limited - Original Registrant

Classifications
5 Pharmaceutical and natural remedies for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations containing siRNA, RNA, shRNA, mRNA or DNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; pharmaceutical medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing siRNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing shRNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing mRNA for treatments in the form of gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing DNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations containing lipids, liposomes or peptides for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing lipids, liposomes or peptides for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in gene therapy for the treatment of tumours; biochemical preparations for medical purposes for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations being nanoparticles for the treatment of cancer; pharmaceutical preparations containing siRNA, RNA, shRNA, mRNA or DNA for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals ; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceutical preparations in the form of nanoparticles; drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; none of the aforesaid for use in relation to the treatment of hair loss or hair growth stimulation
42 Medical and pharmacological research services all in the field of gene therapy and treatment of cancer; biological research, clinical research and medical research all in the field of gene therapy; research in the field of gene therapy; scientific research for medical purposes in the area of cancerous diseases; pharmaceutical product development; research of pharmaceuticals; research relating to pharmaceutical delivery agents; development of pharmaceutical delivery agents; research and development in the pharmaceutical and biotechnology fields; providing information about the results of clinical trials for pharmaceutical products; scientific research services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of pharmaceutical preparations and substances; development of pharmaceuticals and pharmaceutical preparations being nanoparticles; development of pharmaceuticals and pharmaceutical preparations containing siRNA, RNA, shRNA, mRNA or DNA; development of drug delivery agents being made from lipids, liposomes or peptides; development of drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations; development of pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material; development of pharmaceuticals and pharmaceutical preparations for use in gene therapy; development of drug delivery agents for use in gene therapy; development of drug delivery agents being nanoparticles; providing consulting to medical research companies in the design and conduct of clinical trials and proving consulting to pharmaceutical companies in the design of pharmaceutical products

Trademark Events
Jul 14, 2020
Registered-Principal Register
Jun 10, 2020
1(B) Basis Deleted; Proceed To Registration
Apr 29, 2020
Notice Of Allowance Cancelled
Jun 8, 2020
Case Assigned To Intent To Use Paralegal
Apr 29, 2020
Teas Delete 1(B) Basis Received
Apr 28, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Apr 28, 2020
Teas Change Of Correspondence Received
Apr 28, 2020
Teas Change Of Owner Address Received
Apr 21, 2020
Noa E-Mailed - Sou Required From Applicant
Feb 25, 2020
Official Gazette Publication Confirmation E-Mailed
Feb 25, 2020
Published For Opposition
Feb 5, 2020
Notification Of Notice Of Publication E-Mailed
Jan 21, 2020
Approved For Pub - Principal Register
Dec 28, 2019
Teas/Email Correspondence Entered
Dec 27, 2019
Correspondence Received In Law Office
Dec 27, 2019
Teas Response To Office Action Received
Jun 30, 2019
Notification Of Non-Final Action E-Mailed
Jun 30, 2019
Non-Final Action E-Mailed
Jun 30, 2019
Non-Final Action Written
Jun 3, 2019
Teas/Email Correspondence Entered
Jun 3, 2019
Correspondence Received In Law Office
May 30, 2019
Assigned To Lie
May 27, 2019
Teas Response To Office Action Received
Nov 25, 2018
Notification Of Non-Final Action E-Mailed
Nov 25, 2018
Non-Final Action E-Mailed
Nov 25, 2018
Non-Final Action Written
Nov 15, 2018
Assigned To Examiner
Aug 17, 2018
New Application Office Supplied Data Entered In Tram
Aug 13, 2018
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24